Diaceutics CEO, Peter Keeling named in The Business & Finance CEO 100 Index 2022
Diaceutics CEO, Peter Keeling has been named in The Business & Finance CEO 100 Index 2022, which recognises the top 100 Chief Executive Officers working across some of the most innovative companies in Ireland and the UK.
Business & Finance magazine recognised Peter as a thought leader in Personalized Medicine commercialisation, who has driven Diaceutics to become a leader in innovative solutions that enable pharma to leverage diagnostic testing globally. Under his leadership, Diaceutics has grown significantly since its inception in 2005 and now works with 39 of the top pharma companies in the world.
Click here to read more: Business & Finance CEO 100 Index 2022 — Part 2 - Business & Finance | Business & Finance (businessandfinance.com)
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network ®
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network ®
Share:
Newsletter sign up
Sign up to our bi-weekly newsletter covering the latest insights to optimize commercialization of diagnostic driven therapies to help empower your decisions.
READY TO DO COMMERCIALIZATION DIFFERENTLY?
Every patient journey contains opportunities to improve testing, engagement, and adoption. We can help you find them so more people get the right therapy sooner.